The “40:1” printed on an inositol bottle is not a marketing invention, but it also carries more weight on the label than it does in the data.
Quick answer: Myo-inositol and D-chiro-inositol are two forms (stereoisomers) of the same molecule that play different roles in insulin signaling. The 40:1 ratio of myo- to D-chiro- is based on the approximate ratio found in healthy blood plasma, and a few small trials in women with PCOS reported that the combination did as well as or slightly better than myo-inositol alone on some markers. Most of the insulin resistance evidence, however, is for plain myo-inositol, and high doses of D-chiro-inositol by itself have been associated with worse ovarian outcomes in PCOS research.
Two forms, two jobs
Inositol exists in nine possible arrangements. The two that matter here are myo-inositol (MI), the most abundant form in the body and in food, and D-chiro-inositol (DCI), which the body makes from myo-inositol using an enzyme called an epimerase. Insulin stimulates that conversion.
In simplified terms, myo-inositol is involved in glucose uptake into cells, while D-chiro-inositol is more involved in glycogen storage and, in the ovary, in androgen production. Different tissues keep different MI:DCI ratios. Blood plasma runs at roughly 40:1. The ovary normally sits closer to 100:1. Muscle and liver keep more DCI relative to other tissues.
The reason this matters for insulin resistance is a hypothesis sometimes called the “DCI paradox.” In insulin-resistant tissues such as muscle and fat, the conversion of MI to DCI appears to be impaired, leaving those tissues short of DCI. In the ovary of a woman with PCOS, the opposite seems to happen: the ovary stays insulin-sensitive, the high circulating insulin over-drives the conversion, and the ovary ends up with too much DCI and too little MI, which may contribute to higher androgen output and poorer egg quality.
Where the 40:1 ratio came from
Researchers reasoned that if plasma normally sits at about 40:1, supplementing in that same ratio might correct deficits in insulin-resistant tissues without overloading the ovary. A series of small randomized trials in women with PCOS, mostly 40 to 60 participants over three to six months, compared the 40:1 combination against myo-inositol alone or against other ratios.
The reported results were that the 40:1 combination was associated with similar or modestly better improvements in fasting insulin, HOMA-IR, and some hormonal markers compared with myo-inositol alone, and that ratios heavier in DCI did not perform as well on ovarian measures. One often-cited trial compared several ratios and found the 40:1 group had the most favorable ovulation and hormone changes, with the DCI-heavy groups doing worse on those specific outcomes.
That is the whole basis. It is a reasonable basis, but it is a small number of small trials, largely from a few research groups, in one patient population. It has not been tested in men, in people with type 2 diabetes who do not have PCOS, or in long trials with hard outcomes.
What this means if you do not have PCOS
The 40:1 story is mostly an ovary story. The concern about too much DCI is specifically about the ovary. If you are a man with metabolic syndrome, or a woman past menopause, the argument for carefully balancing the ratio is weaker, and the argument for plain myo-inositol, which is where most of the general insulin resistance data sits, is correspondingly stronger. The broader evidence for myo-inositol is reviewed in Myo-Inositol and Insulin Resistance.
Some small studies looked at D-chiro-inositol alone in people with type 2 diabetes decades ago, with mixed results, and that line of research largely stalled. There is not a strong case in the current literature for DCI alone as a metabolic supplement for the general population.
Reading the label
Here is what the supplement facts panel should tell you:
- Milligrams of each form, separately. A 40:1 product delivering the amounts used in trials typically shows about 2,000 mg myo-inositol and 50 mg D-chiro-inositol per serving, taken twice a day. If a label just says “inositol blend 2,050 mg” without the breakdown, you cannot verify the ratio.
- Whether the ratio actually computes. Divide the MI milligrams by the DCI milligrams. Products marketed as 40:1 occasionally list numbers that work out to something else.
- What else is in the capsule. Folic acid is common and was used in many trials. Chromium, berberine, cinnamon, or alpha-lipoic acid in the same product muddy the picture and add interaction questions. Metabolic Clarity Labs sells a berberine product; apply the same scrutiny to MCL that you would to anyone else, and ask your prescriber before stacking anything.
- Powder versus capsules. Four grams of myo-inositol a day is eight 500 mg capsules. Most trials used powder dissolved in water for that reason.
Specific amounts and schedules across the trials are compiled in Inositol Dosage and Timing. The amounts there describe what researchers did; what you should take is a clinician question.
Safety notes specific to the forms
Both forms were generally well tolerated in trials at the amounts used. The main difference in the safety discussion is the concern, in PCOS research, that high-dose D-chiro-inositol alone (well above the 50 to 100 mg range used in combination products) was associated with worse oocyte quality in a fertility setting. That finding is why most clinicians who work with inositol in PCOS steer away from DCI-heavy products.
The lithium and bipolar caution applies to both forms, since inositol is involved in the signaling pathway lithium acts on. If you have a mood disorder or take lithium, this is a psychiatrist conversation before anything else.
Hypoglycemia warning: Combining any blood-sugar-active supplement with insulin, sulfonylureas, or other glucose-lowering medicines can push glucose too low. Symptoms include shakiness, sweating, confusion, and a fast heartbeat. Do not add a supplement to a medication plan without your prescriber’s knowledge.
A fuller safety discussion, including pregnancy and kidney questions, is in Inositol Side Effects and Medication Questions. For primary sources, a PubMed search for the 40:1 trials will turn up the key papers, and the NCCIH guidance on dietary supplements is a sensible frame for any of them.
Questions to bring to your appointment
- Do I have PCOS or a PCOS-like pattern, or is my insulin resistance coming from somewhere else? Does that change which form, if any, makes sense?
- If the 40:1 evidence is mostly about the ovary, is there a reason for me specifically to pay more for the combination over plain myo-inositol?
- Here is my full medication list. Does inositol interact with anything, especially glucose-lowering drugs or anything for mood?
- What would we measure to know if it is doing anything? Fasting insulin, HOMA-IR, cycle regularity, something else?
- How long would you give it before deciding?
- Where does this rank against the lifestyle changes you want me to prioritize first?
The ratio is a legitimate piece of physiology, and the label is not lying to you. But it is answering a question that was asked about ovaries in small PCOS trials. For a general look at how inositol compares with the other options people consider, see the metabolic syndrome supplements hub, and Inositol, PCOS, and Metabolic Syndrome for where the two conditions overlap.
About the author: Charles Kirkland is the founder of Metabolic Clarity Labs and author of The Journey Back. He is not a physician. This is general education, not a medically reviewed treatment plan.
Sources checked October 29, 2026. Discuss personal decisions with a qualified clinician or pharmacist. Do not start, stop, or change prescribed treatment based on this article.
Leave a Reply